Abstract
Background: Biologic drugs, introduced in clinical practice almost twenty years ago, represent nowadays a prominent treatment option in patients with chronic inflammatory arthritis, such as Rheumatoid Arthritis, Psoriatic Arthritis and Spondyloarthritis, that include ankylosing spondylitis and non-radiographic axial spondyloarthritis.
Methods: Several compounds targeting different pathways have been marketed and approved for the treatment of inflammatory arthritis, with a significant impact on the clinical outcomes and the natural history of the diseases.
Results: There are currently seven classes of biologics that are available for the treatment of inflammatory arthritis, each inhibiting a different aspect of the immune-driven inflammatory pathway.
They include:
• Tumor Necrosis Factor (TNF) inhibitors (infliximab, adalimumab, etanercept, golimumab and certolizumab pegol);
• Interleukin-1 (IL-1) receptor antagonists (anakinra);
• Interleukin-6 (IL-6) inhibition (tocilizumab);
• Interleukin-12/23 (IL23) inhibition (ustekinumab);
• Interleukin-17 (IL-17) inhibition (secukinumab);
• B-cell inhibition (anti-CD20, rituximab);
• T-cell costimulation inhibition (anti-CTLA-4, abatacept).
Conclusion: In this review, we will focus on the role of biologic drugs in the treatment strategies for inflammatory arthritis.
Keywords: Biologic drugs, TNF inhibitors, rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, efficacy, safety.
Current Pharmaceutical Biotechnology
Title:Biologics in Inflammatory and Immunomediated Arthritis
Volume: 18 Issue: 12
Author(s): Michele M. Luchetti*, Devis Benfaremo and Armando Gabrielli
Affiliation:
- Dipartimento Scienze Cliniche e Molecolari, Sezione di Clinica Medica, Universita Politecnica delle Marche, Ancona,Italy
Keywords: Biologic drugs, TNF inhibitors, rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, efficacy, safety.
Abstract: Background: Biologic drugs, introduced in clinical practice almost twenty years ago, represent nowadays a prominent treatment option in patients with chronic inflammatory arthritis, such as Rheumatoid Arthritis, Psoriatic Arthritis and Spondyloarthritis, that include ankylosing spondylitis and non-radiographic axial spondyloarthritis.
Methods: Several compounds targeting different pathways have been marketed and approved for the treatment of inflammatory arthritis, with a significant impact on the clinical outcomes and the natural history of the diseases.
Results: There are currently seven classes of biologics that are available for the treatment of inflammatory arthritis, each inhibiting a different aspect of the immune-driven inflammatory pathway.
They include:
• Tumor Necrosis Factor (TNF) inhibitors (infliximab, adalimumab, etanercept, golimumab and certolizumab pegol);
• Interleukin-1 (IL-1) receptor antagonists (anakinra);
• Interleukin-6 (IL-6) inhibition (tocilizumab);
• Interleukin-12/23 (IL23) inhibition (ustekinumab);
• Interleukin-17 (IL-17) inhibition (secukinumab);
• B-cell inhibition (anti-CD20, rituximab);
• T-cell costimulation inhibition (anti-CTLA-4, abatacept).
Conclusion: In this review, we will focus on the role of biologic drugs in the treatment strategies for inflammatory arthritis.
Export Options
About this article
Cite this article as:
Luchetti M. Michele*, Benfaremo Devis and Gabrielli Armando, Biologics in Inflammatory and Immunomediated Arthritis, Current Pharmaceutical Biotechnology 2017; 18 (12) . https://dx.doi.org/10.2174/1389201019666171226151852
DOI https://dx.doi.org/10.2174/1389201019666171226151852 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Essential Fatty Acids - A Review
Current Pharmaceutical Biotechnology Verification between Original and Biosimilar Therapeutic Antibody Infliximab Using nSMOL Coupled LC-MS Bioanalysis in Human Serum
Current Pharmaceutical Biotechnology Vascular and Cardiac Oxidative Stress and Inflammation as Targets for Cardioprotection
Current Pharmaceutical Design Crucial Protein Based Drug Targets and Potential Inhibitors for Osteoporosis: New Hope and Possibilities
Current Drug Targets ADAM8 in Allergy
Inflammation & Allergy - Drug Targets (Discontinued) Neurological Involvement in Rheumatoid Arthritis
Current Immunology Reviews (Discontinued) Comparative Account of Quality Management and Regulatory Aspects of Products with Health Claims: Existing Approaches and Future Challenges for Probiotics and Herbal Products
Applied Clinical Research, Clinical Trials and Regulatory Affairs Anticancer Potential of Dietary Natural Products: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry Role of Vitamins in Neurodegenerative Diseases: A Review
CNS & Neurological Disorders - Drug Targets Immunobiology of Antigen-Specific Immunoglobulin Free Light Chains in Chronic Inflammatory Diseases
Current Pharmaceutical Design Placebos Used in Clinical Trials for Chinese Herbal Medicine
Recent Patents on Inflammation & Allergy Drug Discovery Circulating MicroRNAs as a New Class of Biomarkers of Physiological Reactions of the Organism to the Intake of Dietary Supplements and Drugs
MicroRNA Editorial: The Explosion of Biosimilars in Immune Mediated Chronic Inflammatory Diseases
Current Pharmaceutical Design Biological Predictors of Aging and Potential of FTIR to Study Age-related Diseases and Aging Metabolic Fingerprint
Current Metabolomics p53 Peptide Prevents LITAF-Induced TNF-Alpha-Mediated Mouse Lung Lesions and Endotoxic Shock
Current Molecular Medicine Snake Venom Metalloproteinases: Structure, Mechanism and Induced Diseases
Current Chemical Biology The Use of TNF Family Ligands and Receptors and Agents which Modify their Interaction as Therapeutic Agents
Current Drug Targets Soluble Forms of RAGE in Human Diseases: Clinical and Therapeutical Implications
Current Medicinal Chemistry Structural Comparison of p38 Inhibitor-Protein Complexes: A Review of Recent p38 Inhibitors Having Unique Binding Interactions
Current Topics in Medicinal Chemistry Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?
Current Pharmaceutical Design